Plain-English translation of NCT05777824 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing the best way to decide what follow-up treatment you should receive after surgery for head and neck cancer. You will have already received induction chemotherapy combined with immunotherapy before surgery. Based on how well your cancer responded to that initial treatment and other risk factors, you'll be assigned to receive different combinations of radiation therapy, immunotherapy maintenance treatment, or observation to help prevent your cancer from coming back.
Doctors know that induction chemotherapy and immunotherapy work well against advanced head and neck cancer, but they don't yet know the best follow-up plan after surgery. This trial will help determine whether patients with different levels of cancer response benefit from radiation therapy, continued immunotherapy, both treatments together, or simply monitoring—and which approach helps people live longer with fewer side effects.
You likely qualify if…
You likely don't qualify if…
After your surgery, you'll be placed into one of six groups based on how well your cancer responded to the initial chemotherapy and immunotherapy, and whether you're considered low-risk or high-risk for cancer return. Depending on your group, you may receive radiation therapy (at 50 or 60 Gray doses), continued immunotherapy, chemotherapy combined with radiation and immunotherapy, or simply observation. Researchers will follow you over time to measure whether your cancer stays away, how long you live, and what side effects you experience from treatment.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China